Literature DB >> 19835839

NMR dynamics and antibody recognition of the meningococcal lipidated outer membrane protein LP2086 in micellar solution.

Alessandro Mascioni1, Franklin J Moy, Lisa K McNeil, Ellen Murphy, Breagh E Bentley, Rosaria Camarda, Deborah A Dilts, Pamela S Fink, Viktoria Gusarova, Susan K Hoiseth, Karl Malakian, Terri Mininni, Elena Novikova, Shuo Lin, Scott Sigethy, Gary W Zlotnick, Désirée H H Tsao.   

Abstract

Neisseria meningitidis is a major cause of meningitis. Although protective vaccination is available against some pathogenic serogroups, serogroup B meningococci have been a challenge for vaccinologists. A family of outer membrane lipoproteins, LP2086 (or factor H binding proteins, fHbp), has been shown to elicit bactericidal antibodies and is currently part of a cocktail vaccine candidate. The NMR structure of the variant LP2086-B01 in micellar solution provided insights on the topology of this family of proteins on the biological membrane. Based on flow cytometry experiments on whole meningococcal cells, binding experiments with monoclonal antibodies, and the NMR structure in micellar solution, we previously proposed that LP2086-B01 anchors the outer bacterial membrane through its lipidated N-terminal cysteine, while a flexible 20 residue linker positions the protein above the layer of lipo-oligosaccharides that surrounds the bacteria. This topology was suggested to increase the antigen exposure to the immune system. In the present work, using micellar solution as a membrane mimicking system, we characterized the backbone dynamics of the variant LP2086-B01 in both its lipidated and unlipidated forms. In addition, binding experiments with a Fab fragment derived from the monoclonal MN86-1042-2 were also performed. Our data suggests that due to the length and flexibility of the N-terminal linker, the antigen is not in contact with the micelle, thus making both N- and C-domains highly available to the host immune system. This dynamic model, combined with the binding data obtained with MN86-1042-2, supports our previously proposed arrangement that LP2086-B01 exposes one face to the extracellular space. Binding of MN86-1042-2 antibody shows that the N-domain is the primary target of this monoclonal, providing further indication that this domain is immunologically important for this family of proteins. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19835839     DOI: 10.1016/j.bbamem.2009.09.021

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

Review 1.  Lipoproteins of bacterial pathogens.

Authors:  A Kovacs-Simon; R W Titball; S L Michell
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Structure of the uncomplexed Neisseria meningitidis factor H-binding protein fHbp (rLP2086).

Authors:  Laura Cendron; Daniele Veggi; Enrico Girardi; Giuseppe Zanotti
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-04-20

3.  The role of apolipoprotein N-acyl transferase, Lnt, in the lipidation of factor H binding protein of Neisseria meningitidis strain MC58 and its potential as a drug target.

Authors:  R A G da Silva; C P Churchward; A V Karlyshev; O Eleftheriadou; A K Snabaitis; M R Longman; A Ryan; R Griffin
Journal:  Br J Pharmacol       Date:  2016-12-21       Impact factor: 8.739

4.  Structural basis for cooperativity of human monoclonal antibodies to meningococcal factor H-binding protein.

Authors:  Ilaria Peschiera; Maria Giuliani; Fabiola Giusti; Roberto Melero; Eugenio Paccagnini; Danilo Donnarumma; Werner Pansegrau; José M Carazo; Carlos O S Sorzano; Maria Scarselli; Vega Masignani; Lassi J Liljeroos; Ilaria Ferlenghi
Journal:  Commun Biol       Date:  2019-06-26

5.  Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6.

Authors:  Federica Bianchi; Daniele Veggi; Laura Santini; Francesca Buricchi; Erika Bartolini; Paola Lo Surdo; Manuele Martinelli; Oretta Finco; Vega Masignani; Matthew J Bottomley; Domenico Maione; Roberta Cozzi
Journal:  FASEB J       Date:  2019-10-05       Impact factor: 5.191

6.  Molecular features of lipoprotein CD0873: A potential vaccine against the human pathogen Clostridioides difficile.

Authors:  William J Bradshaw; Jean-François Bruxelle; Andrea Kovacs-Simon; Nicholas J Harmer; Claire Janoir; Severine Péchiné; K Ravi Acharya; Stephen L Michell
Journal:  J Biol Chem       Date:  2019-08-16       Impact factor: 5.157

7.  Variant Signal Peptides of Vaccine Antigen, FHbp, Impair Processing Affecting Surface Localization and Antibody-Mediated Killing in Most Meningococcal Isolates.

Authors:  Ronni A G da Silva; Andrey V Karlyshev; Neil J Oldfield; Karl G Wooldridge; Christopher D Bayliss; Ali Ryan; Ruth Griffin
Journal:  Front Microbiol       Date:  2019-12-19       Impact factor: 5.640

8.  Effect of complement Factor H on antibody repertoire and protection elicited by meningococcal capsular group B vaccines containing Factor H binding protein.

Authors:  Peter T Beernink
Journal:  Hum Vaccin Immunother       Date:  2019-10-22       Impact factor: 3.452

9.  Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes.

Authors:  M Giuliani; E Bartolini; B Galli; L Santini; P Lo Surdo; F Buricchi; M Bruttini; B Benucci; N Pacchiani; L Alleri; D Donnarumma; W Pansegrau; I Peschiera; I Ferlenghi; R Cozzi; N Norais; M M Giuliani; D Maione; M Pizza; R Rappuoli; O Finco; V Masignani
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379

10.  4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.

Authors:  Daniele Veggi; Federica Bianchi; Laura Santini; Paola Lo Surdo; Chelsy C Chesterman; Werner Pansegrau; Nicoletta Bechi; Ying Huang; Vega Masignani; Mariagrazia Pizza; Rino Rappuoli; Matthew J Bottomley; Roberta Cozzi; Domenico Maione
Journal:  PLoS Pathog       Date:  2020-10-02       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.